Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock

Summary

Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.

Timeline

Start

2026-07

Primary completion

2028-09-30

Completion

2028-10-07

Drugs

Indications